- Home
- WES vs INCY Comparison
WES vs INCY Comparison
Compare WES & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WES
- INCY
- Stock Information
- Founded
- WES 2007
- INCY 1991
- Country
- WES United States
- INCY United States
- Employees
- WES N/A
- INCY N/A
- Industry
- WES Natural Gas Distribution
- INCY Biotechnology: Commercial Physical & Biological Resarch
- Sector
- WES Utilities
- INCY Health Care
- Exchange
- WES Nasdaq
- INCY Nasdaq
- Market Cap
- WES 15.7B
- INCY 14.2B
- IPO Year
- WES 2008
- INCY 1993
- Fundamental
- Price
- WES $40.92
- INCY $74.67
- Analyst Decision
- WES Hold
- INCY Buy
- Analyst Count
- WES 9
- INCY 20
- Target Price
- WES $38.00
- INCY $75.12
- AVG Volume (30 Days)
- WES 1.4M
- INCY 1.3M
- Earning Date
- WES 02-26-2025
- INCY 02-10-2025
- Dividend Yield
- WES 8.62%
- INCY N/A
- EPS Growth
- WES 44.12
- INCY N/A
- EPS
- WES 3.91
- INCY 0.15
- Revenue
- WES $3,534,928,000.00
- INCY $4,075,860,000.00
- Revenue This Year
- WES $19.98
- INCY $16.00
- Revenue Next Year
- WES $2.71
- INCY $10.47
- P/E Ratio
- WES $10.43
- INCY $499.49
- Revenue Growth
- WES 16.75
- INCY 12.94
- 52 Week Low
- WES $27.84
- INCY $50.35
- 52 Week High
- WES $43.33
- INCY $83.95
- Technical
- Relative Strength Index (RSI)
- WES 49.91
- INCY 59.31
- Support Level
- WES $39.50
- INCY $72.60
- Resistance Level
- WES $43.11
- INCY $75.18
- Average True Range (ATR)
- WES 1.24
- INCY 1.72
- MACD
- WES -0.16
- INCY 0.18
- Stochastic Oscillator
- WES 33.68
- INCY 74.33
About WES Western Midstream Partners LP Common Units Representing Limited Partner Interests
Western Midstream Partners LP is a US-based company which own, operate, acquire and develop midstream energy assets. The company through its subsidiary is engaged in the business of gathering, processing, compressing, treating and transporting natural gas, condensate, NGLs and crude oil. It owns or has investments in assets located in the Rocky Mountains (Colorado, Utah, and Wyoming), the Mid-Continent (Kansas and Oklahoma), North-central Pennsylvania and Texas.
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.